1. Home
  2. WSO vs INCY Comparison

WSO vs INCY Comparison

Compare WSO & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Watsco Inc.

WSO

Watsco Inc.

HOLD

Current Price

$406.27

Market Cap

16.5B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$98.89

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSO
INCY
Founded
1945
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5B
17.0B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
WSO
INCY
Price
$406.27
$98.89
Analyst Decision
Hold
Buy
Analyst Count
7
21
Target Price
$418.33
$100.63
AVG Volume (30 Days)
393.6K
1.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.24%
N/A
EPS Growth
N/A
4173.33
EPS
N/A
6.41
Revenue
N/A
$3,394,635,000.00
Revenue This Year
$5.49
$11.02
Revenue Next Year
$5.79
$9.97
P/E Ratio
$34.24
$15.28
Revenue Growth
N/A
13.67
52 Week Low
$323.05
$53.56
52 Week High
$533.07
$112.29

Technical Indicators

Market Signals
Indicator
WSO
INCY
Relative Strength Index (RSI) 52.01 43.63
Support Level $400.37 $82.66
Resistance Level $430.44 $108.79
Average True Range (ATR) 15.00 2.89
MACD -2.75 -0.30
Stochastic Oscillator 28.21 28.49

Price Performance

Historical Comparison
WSO
INCY

About WSO Watsco Inc.

Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: